Moreover, numerous studies demonstrated that high CD47 expression was correlated with poor disease survival, indicating that CD47 could act as an adverse prognostic factor in numerous cancers, including myeloid leukaemia, prostate carcinoma, lung carcinoma, breast carcinoma and hepatocellular cancer [4, 5, 6, 7]. This evidence concerns the gene CD47 and lung carcinoma.